Clinical score for colorectal cancer patients with lung-limited metastases undergoing surgical resection: Meta-Lung Score

Ziranu, Pina; Ferrari, Paolo Albino; Guerrera, Francesco; Bertoglio, Pietro; Tamburrini, Alessandro; Pretta, Andrea; Lyberis, Paraskevas; Grimaldi, Giulia; Lai, Eleonora; Santoru, Massimiliano; Bardanzellu, Fabio; Riva, Laura; Balconi, Francesca; Della Beffa, Eleonora; Dubois, Marco; Pinna-Susnik, Matteo; Donisi, Clelia; Capozzi, Enrico; Pusceddu, Valeria; Murenu, Alessandro; Puzzoni, Marco; Mathieu, Federico; Sarais, Sabrina; Alzetani, Aiman; Luzzi, Luca; Solli, Piergiorgio; Paladini, Piero; Ruffini, Enrico; Cherchi, Roberto; Scartozzi, Mario

doi:10.1016/j.lungcan.2023.107342

Cited by 4 publications

(1 citation statement)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 5-year survival rate in patients scoring 0 points was 88%, while no patients scoring 1 were still alive at 2 years. Moreover-although not inserted in the meta-lung score-the BRAF mutation was confirmed to be associated with a poor prognosis, while adjuvant chemotherapy did not add any significant benefit in OS [55].…”

Section: Principles Of Surgical Resectionmentioning

confidence: 89%

Colorectal Cancer Pulmonary Metastasectomy: When, Why and How

Petrella,

Danuzzo,

Sibilia

et al. 2024

Cancers

View full text Add to dashboard Cite

Colorectal cancer is the third-most-diagnosed cancer in males and in females, representing 8% of estimated new cases, and the third cause of cancer-related death in both sexes, accounting for 9% of cancer deaths in men and 8% in women. About 20% of patients diagnosed with CRC present metastatic disease. Although lung metachronous or synchronous metastatic spread without other involved sites has been reported in only a small proportion of patients, considering that this tumor is frequently diagnosed, the clinical approach to CRC pulmonary metastases represents a major issue for thoracic surgeons and CRC oncologists. Among patients diagnosed with pulmonary metastases from CRC, about 9–12% are eligible for local treatments with radical intent, including surgical resection, SBRT (stereotactic body radiation therapy) and ablation therapy. Due to the lack of randomized controlled trials among different local strategies, there is no definitive evidence about the optimal approach, although surgical resection is considered the most effective therapeutic option in this clinical scenario. Oncological achievement of primary radical resection, the biology of primary tumor and metastatic sites, disease free interval and or progression free survival are independent prognostic factors which make it possible to define a cohort of patients which might significantly benefit from pulmonary metastasectomy.

show abstract

Section: Principles Of Surgical Resectionmentioning

confidence: 89%

Colorectal Cancer Pulmonary Metastasectomy: When, Why and How

Petrella,

Danuzzo,

Sibilia

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

Recurrence-free survival curve for pulmonary metastasectomy in colorectal cancer plateaus at 3 years

Yoshida,

Chang,

Okamoto

et al. 2024

Updates Surg

View full text Add to dashboard Cite

Colorectal Cancer Pulmonary Metastasectomy: When, Why and How

Petrella,

Danuzzo,

Sibilia

et al. 2024

Preprint

View full text Add to dashboard Cite

Colorectal cancer is the third most diagnosed cancer in males and in females, representing 8% of estimated new cases and the third cause of cancer-related death in both sexes, accounting for 9% of cancer deaths in men and 8% in women. About 20% of patients diagnosed with CRC present metastatic disease. Although lung metachronous or synchronous metastatic spread without other involved sites has been reported in only a small proportion of patients, considering that this tumor is frequently diagnosed, the clinical approach to CRC pulmonary metastases represents a major issue for thoracic surgeons and CRC oncologists. Among patients diagnosed with pulmonary metastases from CRC, about 9 – 12% are eligible for local treatments with radical intent, including surgical resection, SBRT and ablation therapy. Due to the lack of randomized controlled trials among different local strategies, there is no definitive evidence about the optimal approach, although surgical resection is considered the most effective therapeutic option in this clinical scenario. Oncological achievement of primary radical resection, the biology of primary tumor and metastatic sites, disease free interval and or progression free survival are independent prognostic factors which make it possible to define a cohort of patients which might significantly benefit from pulmonary metastasectomy.

show abstract

Clinical score for colorectal cancer patients with lung-limited metastases undergoing surgical resection: Meta-Lung Score

Cited by 4 publications

References 48 publications

Colorectal Cancer Pulmonary Metastasectomy: When, Why and How

Colorectal Cancer Pulmonary Metastasectomy: When, Why and How

Recurrence-free survival curve for pulmonary metastasectomy in colorectal cancer plateaus at 3 years

Colorectal Cancer Pulmonary Metastasectomy: When, Why and How

Contact Info

Product

Resources

About